Sandoz announces collaboration with mAbxience to expand patient access to life — enhancing biosimilar medicines

Sandoz Group AG / Key word(s): Agreement Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines 18.09.2026 / 07:15 CET/CEST ══════════════════════════════════════════════════════════════════════════════════════════════════════ Media Release • Agreement for emicizumab biosimilar in reference market worth USD 5.7 billion; marks first haemophilia biosimilar in pipeline • Provides basis for evaluating potential future collaboration opportunities based on shared commitment to expanding access to biosimilar medicines • Strengthens Sandoz position in biosimilars and further expands industry-leading pipeline to 40 assets; continues momentum following agreements with Henlius and Samsung Bioepis • Reinforces commitment to expand patient access by capturing significant share of unprecedented upcoming biosimilar loss-of-exclusivity market opportunity Basel, 18 September 2026 — Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announces a licensing, development, manufacturing and commercialisation agreement with mAbxience, marking another significant step to broaden patient access to high-quality biosimilar medi